Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioLineRx ADS Representing 15 Ord Shs BLRX

Healthcare Biotechnology
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform ,... see more

Recent & Breaking News (NDAQ:BLRX)

BioLineRx to Report Third Quarter 2015 Results on November 16, 2015

Business Wire November 9, 2015

BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML

Business Wire November 5, 2015

BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia

Business Wire September 10, 2015

BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Submitted for CE Mark Registration

Business Wire September 9, 2015

BioLineRx to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York

Business Wire September 3, 2015

BioLineRx Reports Second Quarter 2015 Financial Results

Business Wire August 20, 2015

BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment

Business Wire August 17, 2015

BioLineRx to Report Second Quarter 2015 Results on August 20, 2015

Business Wire August 13, 2015

BioLineRx Announces Top-Line Results from Bellerophon's PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BL-1040)

Business Wire July 27, 2015

BioLineRx to Present Successful Results of Phase 1/2 Study for Novel Celiac Treatment at International Celiac Disease Symposium

Business Wire June 17, 2015

BioLineRx to Present at the JMP Securities Life Sciences Conference in New York

Business Wire June 16, 2015

BioLineRx Presents Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference

Business Wire June 15, 2015

Research Underlying BioLineRx's Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award

Business Wire June 3, 2015

BioLineRx Announces Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions

Business Wire June 1, 2015

BioLineRx to Present Positive Safety and Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at the European Hematology Annual Congress

Business Wire May 27, 2015

BioLineRx Reports First Quarter 2015 Financial Results

Business Wire May 18, 2015

BioLineRx to Report First Quarter 2015 Results on May 18, 2015

Business Wire May 11, 2015

BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia

Business Wire May 4, 2015

BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment

Business Wire March 25, 2015

BioLineRx Reports Year End 2014 Financial Results

Business Wire March 23, 2015